The American Lung Association estimates that 1 in 30 Americans is a carrier of CF.

“Currently available treatments focus on treating the symptoms of the disease, while we address the underlying genetic cause of the disease, thereby offering hope of an easy-to-use and less frequent treatment approach,” said SpliSense CEO Gili Hart, PhD.
“This program is our first-in-human and will serve as proof of concept of our pulmonary platform for our additional promising programs, including muco-obstructive diseases and IPF, the latter of which is expected to enter the clinic next year.”